StockData

GT Biopharma vs TuHURA Biosciences

GTBP and HURA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GTBP and HURA compare

GT Biopharma is the larger company, worth 1.8 times as much as TuHURA Biosciences ($155M against $87.3M).

GT Biopharma scores higher on the StockData Score (5 against 0 for TuHURA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGTBPHURA
Size and price
Market cap$155M$87.3M
Share price$3.43$1.37
Change, 1 year−80.0%−27.1%
Change, 5 years−99.9%−99.9%
Beta (5Y)0.821.03
Employees122
StockData Score
Total score5 (better)0
Valuation score00
Growth score00
Performance score00
Health score5 (better)0
Dividend score00
Valuation
P/B26.7×4.7× (better)
FCF yield–−34.3%
Profitability
Return on equity−231%−161% (better)
Financial health
Debt / equity0.00–
Current ratio3.50 (better)0.18
Altman Z-score−90.79−3.30 (better)
Piotroski F-score3 (better)2
Dividends and buybacks
Buyback yield–−23.1%
Shareholder yield0.00% (better)−23.1%
Ownership
Held by institutions–14.1%
Held by insiders1.9%4.9%
Short interest, % of float0.56%10.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.